Research Summary
Dr. Handy Marshall's research focuses on the relationship between cardiovascular disease and cancer, clinical trials in advanced prostate cancer, and genetics in prostate cancer.
Selected Publications
View all on PubMed
Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2018 Aug 31. doi: 10.1038/s41391-018-0086-1. [Epub ahead of print] PubMed PMID: 30171229.
Handy CE, Quispe R, Pinto X, Blaha MJ, Blumenthal RS, Michos ED, Lima JAC, Guallar E, Ryu S, Cho J, Kaye JA, Comin-Colet J, Corbella X, Cainzos-Achirica M. Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment. Circulation. 2018 Aug 14;138(7):727-734. doi: 10.1161/CIRCULATIONAHA.118.035516. PubMed PMID: 30359131.
Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018 Apr;14(10):907-917. doi: 10.2217/fon-2017-0531. Epub 2017 Dec 20. Review. PubMed PMID: 29260582; PubMed Central PMCID: PMC5925432.
Handy CE, Antonarakis ES. Sequencing Treatment for Castration-Resistant Prostate Cancer. Curr Treat Options Oncol. 2016 Dec;17(12):64. Review. PubMed PMID: 27822685.
Handy Marshall C, Nahas-Vigon J, Manesh R, Gelber AC. Just Beneath the Surface. N Engl J Med. 2018 Sep 6;379(10):968-973. doi: 10.1056/NEJMcps1802664. PubMed PMID: 30184453.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.